Research groups
Websites
-
MRC Molecular Haematology Unit
Research Unit
-
MRC Weatherall Institute of Molecular Medicine
Research Institute
-
Oxford Centre for Haematology
Virtual Centre
-
National Institute for Health Research
Senior Fellow
Paresh Vyas
MRCP FRCP FRCPath
Professor of Haematology
- Consultant Physician
Normal and Leukaemic stem/progenitor cell biology
Our aim is to characterise the heterogeneous populations of leukaemia propagating cells in adult and childhood Acute Myeloid Leukaemia (AML) at functional, genetic, epigenetic and molecular levels, eventually at a single cell level, to improve our basic understanding of leukaemia initiation and propagation. The ultimate aim is to translate this knowledge to improve survival rates in patients.
Biography
Paresh Vyas is Professor of Haematology at the University of Oxford. He studied medicine at Cambridge then Oxford. After completing his medical and haematology training in London, he did his PhD with Professor Doug Higgs and Professor Sir David Weatherall at the MRC Molecular Haematology Unit, Oxford. A three-year post-doctoral fellowship with Professor Stuart Orkin at Harvard University followed. He is a research-active Consultant Haematologist with a clinical practice in myeloid disorders: myelodysplastic syndrome, MDS, acute myeloid leukaemia, AML, and myeloproliferative disorders, MPD, as well as allogeneic stem cell transplant. His research in the MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, focuses on molecular and cellular biology of AML and MDS with specific interest in purification and therapeutic targeting of myeloid stem cells. He studies single cell biology in normal and leukaemic haemopoiesis. He is on the UK AML and MDS clinical trial groups. He is co-Lead of the Oxford BRC Haematology and Stem Cells Theme, is on the Board of NHSBT, vice-chair of the MRC Clinical Training Panel and Translational Lead for the UK Therapy Acceleration Program.
Key publications
-
C/EBPalpha and GATA-2 mutations induce bi-lineage acute erythroid leukemia through transformation of a neomorphic neutrophil-erythroid progenitor
Journal article
NERLOV C. et al, (2020), Cancer Cell
-
Journal article
Labuhn M. et al, (2019), Cancer Cell
-
Clonal Heterogeneity of Acute Myeloid Leukemia Treated with the IDH2 inhibitor Enasidenib
Journal article
Vyas P. et al, (2018), Nature Medicine
-
Journal article
Karamitros D. et al, (2018), Nat Immunol, 19, 85 - 97
-
Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.
Journal article
Quek L. et al, (2016), The Journal of experimental medicine, 213, 1513 - 1535
-
Journal article
Goardon N. et al, (2011), Cancer Cell, 19, 138 - 152
Recent publications
-
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Journal article
Daver NG. et al, (2022), Cancer Discovery, OF1 - OF14
-
A Phase 3, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy (ENHANCE-3)
Conference paper
Daver N. et al, (2022), AMERICAN JOURNAL OF HEMATOLOGY, 97, S5 - S5
-
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia
Conference paper
Daver N. et al, (2022), AMERICAN JOURNAL OF HEMATOLOGY, 97, S5 - S6
-
AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions
Journal article
Daver N. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S231 - S232
-
AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
Journal article
Lachowiez C. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S240 - S241